评论：米非司酮作为堕胎药使用相关严重不良事件的分析。 - Suppr

Suppr

超能文献

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

作者信息

Hausknecht Richard U

出版信息

Ann Pharmacother. 2006 Apr;40(4):785-6; author reply 786. doi: 10.1345/aph.1G481c. Epub 2006 Mar 28.

DOI:10.1345/aph.1G481c

PMID:16569806

Abstract

摘要

相似文献

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Apr;40(4):785-6; author reply 786. doi: 10.1345/aph.1G481c. Epub 2006 Mar 28.

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Apr;40(4):784; author reply 784-5. doi: 10.1345/aph.1G481a. Epub 2006 Mar 7.

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Jun;40(6):1215-6; author reply 1216-7. doi: 10.1345/aph.1G481d. Epub 2006 May 30.

Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.

Contraception. 2015 Sep;92(3):179-81. doi: 10.1016/j.contraception.2015.06.016. Epub 2015 Jun 18.

Analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Feb;40(2):191-7. doi: 10.1345/aph.1G481. Epub 2005 Dec 27.

[Medical abortion].

Ugeskr Laeger. 1999 May 31;161(22):3263.

Her accidental legacy.

Newsweek. 2003 Oct 13;142(15):64.

Safety of mifepristone abortions in clinical use.

Contraception. 2005 Sep;72(3):175-8. doi: 10.1016/j.contraception.2005.03.011.

Mifepristone: less obvious adverse effects.

Ann Pharmacother. 2001 Mar;35(3):381-2. doi: 10.1345/aph.10410.

Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial.

BJOG. 2009 Feb;116(3):381-9. doi: 10.1111/j.1471-0528.2008.02034.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Apr;40(4):785-6; author reply 786. doi: 10.1345/aph.1G481c. Epub 2006 Mar 28.

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Apr;40(4):784; author reply 784-5. doi: 10.1345/aph.1G481a. Epub 2006 Mar 7.

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Jun;40(6):1215-6; author reply 1216-7. doi: 10.1345/aph.1G481d. Epub 2006 May 30.

Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.

Contraception. 2015 Sep;92(3):179-81. doi: 10.1016/j.contraception.2015.06.016. Epub 2015 Jun 18.

Analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Ann Pharmacother. 2006 Feb;40(2):191-7. doi: 10.1345/aph.1G481. Epub 2005 Dec 27.

[Medical abortion].

Ugeskr Laeger. 1999 May 31;161(22):3263.

Her accidental legacy.

Newsweek. 2003 Oct 13;142(15):64.

Safety of mifepristone abortions in clinical use.

Contraception. 2005 Sep;72(3):175-8. doi: 10.1016/j.contraception.2005.03.011.

Mifepristone: less obvious adverse effects.

Ann Pharmacother. 2001 Mar;35(3):381-2. doi: 10.1345/aph.10410.

Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial.

BJOG. 2009 Feb;116(3):381-9. doi: 10.1111/j.1471-0528.2008.02034.x.